Overview
The goal of this prospective single-arm trial is to investigate the accuracy and feasibility of the para-aortic lymph node metastasis prediction model in locally advanced cervical cancer, as well as its impact on patients' prognosis. The main questions it aims to answer
- are
-
- Is the para-aortic lymph node metastasis prediction model accurate and feasible?
- Whether the para-aortic lymph node metastasis prediction model can affect the prognosis of patients.
Eligibility
Inclusion Criteria:
- In 2018, the International Federation of Obstetrics and Gynecology (FIGO) stage was Ib3 IIA2-IVA;
- It was treated initially without surgical and chemotherapy.
- Squamous cell carcinoma, adenocarcinoma and adeno-squamous cell carcinoma were confirmed by histopathology.
- Pelvic MRI ± abdominal CT or MRI or PET/CT were performed before treatment.
- ECOG score:0 ~ 1.
- The expected survival time>6 months;
- There is no absolute contraindication of surgery and and chemoradiotherapy and the patients with good compliance.
Exclusion Criteria:
- History of immune disease who need to take immunosuppressive drugs.
- History of serious mental illness and brain functional disorder.
- Other malignancies were diagnosed within five years or needed treatments.
- Those who are unable or unwilling to accept surgical treatment/sign informed consent/comply with research requirements.
- Without surgical conditions: 1) Chronic renal insufficiency or renal failure; 2) Liver insufficiency; 3)Chronic lung disease with restrictive respiratory dysfunction; 4) Cardiac dysfunction (patients with relative and absolute contraindications to surgery after consultation by cardiac physicians.
- Patients who cannot understand the research regimen and refuse to sign the informed consent form.
- Other concomitant diseases or special conditions seriously endanger the patient's health or interfere with the trial.